December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
A New Model of Age-related Macular Degeneration Induced by Advanced Glycation End Products
Author Affiliations & Notes
  • T Yasukawa
    Ophthalmology University Eye Hospital Leipzig Leipzig Germany
  • S Hoffmann
    Ophthalmology University Eye Hospital Leipzig Leipzig Germany
  • U Friedrichs
    Ophthalmology University Eye Hospital Leipzig Leipzig Germany
  • W Eichler
    Ophthalmology University Eye Hospital Leipzig Leipzig Germany
  • Y-S Wang
    Ophthalmology University Eye Hospital Leipzig Leipzig Germany
  • P Wiedemann
    Ophthalmology University Eye Hospital Leipzig Leipzig Germany
  • Footnotes
    Commercial Relationships   T. Yasukawa, None; S. Hoffmann, None; U. Friedrichs, None; W. Eichler, None; Y. Wang, None; P. Wiedemann, None.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 2805. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T Yasukawa, S Hoffmann, U Friedrichs, W Eichler, Y-S Wang, P Wiedemann; A New Model of Age-related Macular Degeneration Induced by Advanced Glycation End Products . Invest. Ophthalmol. Vis. Sci. 2002;43(13):2805.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Recently, it has been reported that advanced glycation end products (AGEs) might be associated with age-related macular degeneration (AMD). The object of this study was to investigate whether a new model of AMD could be developed by subretinal implantation of glycated albumin-microspheres in rabbits. Methods: Glycated albumin was prepared with incubation of rabbit serum albumin (RSA) with glycolaldehyde for 4 hours at 37 degree and used as AGE. AGE-microspheres [MS(AGE)] were made through crosslinking albumin by glycolaldehyde and glutaraldehyde, and non-glycated RSA-microspheres [MS(RSA)] only by glutaraldehyde. Five hundred µg of RSA, AGE, MS(RSA), or MS(AGE) were injected into the subretinal space of rabbit eyes. Eyes were followed up 1, 2, 4, 8 and 12 weeks after operation by ophthalmoscopy and fluorescein angiography. The eyes enucleated 4 or 12 weeks after operation were evaluated by light and fluorescein microscopy. Results: While RSA had no particular effect on the retina, the eyes administered with AGE showed slight fluorescein leakage at week 4, resulting in retinal atrophy at week 12. MS(RSA) exhibited fluorescein leakage on fluorescein angiography at week 8, but histologically only disturbance of retinal cell layer without subretinal neovascularization at week 12. The eyes injected with MS(AGE) showed fluorescein leakage 2 weeks after implantation. This leakage was sustained throughout the following period for observation. In the eyes with MS(AGE) at week 4, histologic examination revealed that there were many microspheres remaining mainly in the cytoplasm of retinal pigment epithelial cells (RPECs), drusen-like and basal laminar deposit-like formations, macrophages adhering to the basal side of retinal pigment epithelium (RPE), and a microspheres-phagocytosing RPEC overlaid with other RPECs. Another eye with MS(AGE) at week 12 showed focal choroidal neovascularization and subsequent severe retinal atrophy. Conclusion: Subretinal implantation of AGE-modified microspheres induced various findings similar to characteristics of AMD. This model may be useful for elucidating the relationship of AGEs with AMD and the pathology of AMD.

Keywords: 308 age-related macular degeneration • 316 animal model • 346 choroid: neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×